CCL2 and breast carcinoma: In fact, the secretion of CCL2 by tumor cells has been observed in a variety of cancer types, such as esophageal carcinoma [29], bladder cancer [30], breast cancer [31], melanoma [32], and colorectal cancer (CRC) [33], leading to enhanced TAM infiltration in TME.